Spyre Therapeutics, Inc. SYRE Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $97.19M+13.4% | $85.72M+32.1% | $64.9M-20.5% | $81.66M+68.4% | $48.49M-45.8% | ||
| $644.28M-4.0% | $670.81M+59.2% | $421.3M-5.3% | $444.92M-13.8% | $516.33M+0.5% | ||
| $22.49M+5.8% | $21.25M+15.4% | $18.41M+50.2% | $12.25M+148% | $4.95M-8.1% | ||
| $419.2M-4.9% | $440.9M+59.3% | $276.69M-15.6% | $327.76M-10.7% | $367.11M+8.5% | ||
| $56.95M+113% | $26.68M— | —— | —— | —— | ||
| $763.95M-1.8% | $777.78M+54.1% | $504.6M-6.4% | $538.83M-5.4% | $569.77M-6.4% | ||
| $763.95M-1.8% | $777.78M+54.1% | $504.6M-6.4% | $538.83M-5.4% | $569.78M-6.4% | ||
| $29.16M+8.2% | $26.95M+13.1% | $23.83M+22.7% | $19.42M-10.2% | $21.63M-21.9% | ||
| $5.07M-36.2% | $7.94M+54.7% | $5.13M+56.0% | $3.29M+111% | $1.56M-72.6% | ||
| $85.16M+45.1% | $58.69M+26.8% | $46.27M-44.3% | $83.06M+17.5% | $70.68M+30.7% | ||
| $1.29M— | $0— | —— | —— | —— | ||
| $56.95M+113% | $26.68M-46.1% | $49.5M-40.4% | $83.06M-4.7% | $87.17M-3.9% | ||
| 400M0.0% | 400M0.0% | 400M0.0% | 400M0.0% | 400M+3,076,823% | ||
| $1.71B+1.6% | $1.69B+23.7% | $1.36B+0.8% | $1.35B+0.8% | $1.34B+0.7% | ||
| -$1.2B-6.1% | -$1.13B-5.9% | -$1.07B-1.1% | -$1.05B-3.6% | -$1.02B-4.6% | ||
| -$767K-188% | $869K+9.9% | $791K+74.2% | $454K-33.4% | $682K+279% | ||
| $670.81M-6.2% | $715.24M+57.2% | $455.1M-0.1% | $455.77M-5.6% | $482.61M-6.8% | ||
| $763.95M-1.8% | $777.78M+54.1% | $504.6M-6.4% | $538.83M-5.4% | $569.78M-6.4% | ||
| $645.05M-3.7% | $669.94M+59.3% | $420.51M-5.4% | $444.47M-13.8% | $515.68M+0.4% | ||
| $0— | $0-100% | $8M— | $0— | $0— | ||
| $0— | $0-100% | $8M— | $0— | $0— | ||
| $432M+139% | $180.96M+358% | $39.47M-76.9% | $170.61M+62.3% | $105.15M-57.8% | ||
| $432M+139% | $180.96M+358% | $39.47M-76.9% | $170.61M+62.3% | $105.15M-57.8% | ||
| $1.06M+811% | $116K+205% | $38K-75.2% | $153K-5.0% | $161K-67.3% | ||
| $0— | $0-100% | $8M— | $0— | $0— | ||
| $432M+139% | $180.96M+281% | $47.47M-72.2% | $170.61M+62.3% | $105.15M-57.8% | ||
| $432M+139% | $180.96M+358% | $39.47M-76.9% | $170.61M+62.3% | $105.15M-57.8% | ||
| $432M+139% | $180.96M+281% | $47.47M-72.2% | $170.61M+62.3% | $105.15M-57.8% | ||
| $644.28M-4.0% | $670.81M+59.2% | $421.3M-5.3% | $444.92M-13.8% | $516.33M+0.5% | ||
| $741.5M— | —— | —— | —— | —— | ||
| $645.05M-3.7% | $669.94M+59.3% | $420.51M-5.4% | $444.47M-13.8% | $515.68M+0.4% | ||
| $50.26M+120% | $22.82M+107% | $11.02M-81.6% | $59.9M+39.9% | $42.81M+70.7% | ||
| $50.26M+120% | $22.82M+107% | $11.02M-81.6% | $59.9M+39.9% | $42.81M+70.7% | ||
| $1.42M+1.4% | $1.4M+24.9% | $1.12M+29.6% | $867K+39.6% | $621K-6.1% | ||
| $6.69M+73.3% | $3.86M+19.5% | $3.23M— | $0-100% | $16.49M-55.0% | ||
| $29.16M+8.2% | $26.95M+13.1% | $23.83M+22.7% | $19.42M-10.2% | $21.63M-21.9% | ||
| $0— | $0-100% | $8K— | $0— | $0— | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | ||
| 78.8M+0.8% | 78.2M+29.3% | 60.5M+0.2% | 60.4M+0.2% | 60.3M0.0% | ||
| $1.71B+1.6% | $1.69B+23.7% | $1.36B+0.8% | $1.35B+0.8% | $1.34B+0.7% | ||
| $15K0.0% | $15K+15.4% | $13K0.0% | $13K0.0% | $13K0.0% | ||
| $432M+139% | $180.96M+281% | $47.47M-72.2% | $170.61M+62.3% | $105.15M-57.8% | ||
| $290K-70.6% | $986K+18.9% | $829K+36.6% | $607K-24.8% | $807K+24.0% | ||
| $1.06M+811% | $116K+205% | $38K-75.2% | $153K-5.0% | $161K-67.3% | ||
| $645.05M-3.7% | $669.94M+59.3% | $420.51M-5.4% | $444.47M-13.8% | $515.68M+0.4% | ||
| $56.95M+113% | $26.68M— | —— | —— | —— | ||
| $22.5M+29.2% | $17.42M+0.1% | $17.4M+15.9% | $15.02M-21.3% | $19.08M-8.5% | ||
| $1.42M+1.4% | $1.4M+24.9% | $1.12M+29.6% | $867K+39.6% | $621K-6.1% | ||
| $1.06M+811% | $116K+205% | $38K-75.2% | $153K-5.0% | $161K-67.3% | ||
| $290K-70.6% | $986K+18.9% | $829K+36.6% | $607K-24.8% | $807K+24.0% | ||
| $645.05M-3.7% | $669.94M+59.3% | $420.51M-5.4% | $444.47M-13.8% | $515.68M+0.4% | ||
| $419.2M-4.9% | $440.9M+59.3% | $276.69M-15.6% | $327.76M-10.7% | $367.11M+8.5% | ||
| $0— | $0— | $0— | $0— | $0-100% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $00.0% | $00.0% | $00.0% | $00.0% | $00.0% | ||
| $400M0.0% | $400M0.0% | $400M0.0% | $400M0.0% | $400M0.0% | ||
| $78.84M+0.8% | $78.19M+29.3% | $60.47M+0.2% | $60.37M+0.2% | $60.28M0.0% | ||
| $78.84M+0.8% | $78.19M+29.3% | $60.47M+0.2% | $60.37M+0.2% | $60.28M0.0% | ||
| $0— | $0-100% | $8K— | $0— | $0— | ||
| $432M+139% | $180.96M+358% | $39.47M-76.9% | $170.61M+62.3% | $105.15M-57.8% | ||
| $0— | $0-100% | $8M— | $0— | $0— | ||
| $1.06M+811% | $116K+287% | $30K-80.4% | $153K-5.0% | $161K-67.3% | ||
| $225.08M-2.1% | $229.92M+59.0% | $144.61M+23.4% | $117.16M-21.5% | $149.22M-14.8% | ||
| $1.06M+811% | $116K+205% | $38K-75.2% | $153K-5.0% | $161K-67.3% | ||
| $432M+139% | $180.96M+281% | $47.47M-72.2% | $170.61M+62.3% | $105.15M-57.8% | ||
| $56.95M+113% | $26.68M— | —— | —— | —— | ||
| $6.69M+73.3% | $3.86M+19.5% | $3.23M— | $0-100% | $16.49M-55.0% | ||
| 2— | —— | 20.0% | 20.0% | 2— | ||
| $165K-7.8% | $179K+5.3% | $170K-29.8% | $242K-34.8% | $371K-25.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Spyre Therapeutics, Inc.'s total assets?
- Spyre Therapeutics, Inc. (SYRE) holds $764.0M in total assets, up 34.1% year over year.
- How much cash does Spyre Therapeutics, Inc. have?
- Spyre Therapeutics, Inc. holds $97.2M in cash and equivalents.
- Can Spyre Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 8.97 — current assets exceed current liabilities.
- Where does Spyre Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.